Their pharmacological action is based on gut incretin hormones, the glucose-dependent insulinotropic peptide (GIP), and the glucagon like peptide-1 (GLP-1), which appear to be malfunctioning in T2DM and have important effects on insulin and glucagon secretion [24, 25]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.